Stock Events

Stock Events

Enzolytics 

$0.000500
50
+$0.00+0% Thursday 18:37

Statistics

Day High
0.0006
Day Low
0.0004
52W High
0.0013
52W Low
0.0002
Volume
4,189,938
Avg. Volume
5,032,888
Mkt Cap
2.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
May 12
$150.00
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30JunExpected
Q3 2016
Q4 2016
Q1 2017
Q2 2017
Q3 2017
Q4 2017
Q1 2018
-0
-0
0
0
Expected EPS
N/A
Actual EPS
-0.0008

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-394,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENZC. It's not an investment recommendation.
Schwab US Dividend Equity
7
SCHD
Coca-Cola
7
KO
Realty Income
6
O
Tesla
5
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets treatments for HIV/AIDS, liver diseases, cancer, and inflammatory and respiratory diseases, competing directly with Enzolytics' focus on infectious diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for treating cancer, eye diseases, and infectious diseases, making it a direct competitor in the biotech space.
Moderna
MRNA
Mkt Cap55.09B
Moderna is known for its mRNA technology used in vaccines, directly competing with Enzolytics' efforts in developing treatments for infectious diseases, including HIV and COVID-19.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech SE operates in the biotechnology industry focusing on patient-specific immunotherapies for cancer and infectious diseases, competing with Enzolytics in the infectious disease sector.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical corporation with a broad portfolio, including vaccines and drugs for infectious diseases, directly competing with Enzolytics' therapeutic and vaccine development.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines for infectious diseases, posing competition to Enzolytics' similar focus areas.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a biotechnology company that develops vaccines for infectious diseases, including COVID-19, directly competing with Enzolytics' research and development in infectious disease vaccines.
Arbutus Biopharma
ABUS
Mkt Cap1B
Arbutus Biopharma Corporation focuses on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a direct competitor in the viral infection treatment space.
IN8bio
INAB
Mkt Cap10.2M
IN8bio, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases and cancer, making it a competitor in the biotech and infectious disease market.

About

Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).
Show more...
CEO
Steven Sharabura
Employees
1
Country
United States
ISIN
US2941121079

Listings

OTC Link
US
ENZC

0 Comments

Share your thoughts

FAQ

What is Enzolytics stock price today?▼
The current price of ENZC is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Enzolytics stock price performance more closely on the chart.
What is Enzolytics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Enzolytics stocks are traded under the ticker ENZC.
Is Enzolytics stock price growing?▼
ENZC stock has fallen by -16.67% compared to the previous week, the month change is a -0% fall, over the last year Enzolytics has showed a -23.08% decrease.
What is Enzolytics market cap?▼
Today Enzolytics has the market capitalization of 2.42M
What were Enzolytics earnings last quarter?▼
ENZC earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enzolytics revenue for the last year?▼
Enzolytics revenue for the last year amounts to 0 USD.
What is Enzolytics net income for the last year?▼
ENZC net income for the last year is -394,000 USD.
Does Enzolytics pay dividends?▼
Yes, ENZC dividends are paid en. The last dividend per share was 150 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Enzolytics have?▼
As of September 04, 2026, the company has 1 employees.
In which sector is Enzolytics located?▼
Enzolytics operates in the Health & Wellness sector.
When did Enzolytics complete a stock split?▼
The last stock split for Enzolytics was on February 07, 2013 with a ratio of 1:500.
Where is Enzolytics headquartered?▼
Enzolytics is headquartered in Plano, United States.